80 related articles for article (PubMed ID: 1705688)
1. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.
Laneuville P; Heisterkamp N; Groffen J
Oncogene; 1991 Feb; 6(2):275-82. PubMed ID: 1705688
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
3. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
4. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
[TBL] [Abstract][Full Text] [Related]
5. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
6. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors.
Laneuville P; Timm M; Hudson AT
Cancer Res; 1994 Mar; 54(5):1360-6. PubMed ID: 8118826
[TBL] [Abstract][Full Text] [Related]
7. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
9. Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Cambier N; Zhang Y; Vairo G; Kosmopoulos K; Metcalf D; Nicola NA; Elefanty AG
Oncogene; 1999 Jan; 18(2):343-52. PubMed ID: 9927191
[TBL] [Abstract][Full Text] [Related]
10. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
[TBL] [Abstract][Full Text] [Related]
11. Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.
Chalandon Y; Jiang X; Loutet S; Eaves AC; Eaves CJ
Leukemia; 2004 May; 18(5):1006-12. PubMed ID: 15014528
[TBL] [Abstract][Full Text] [Related]
12. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).
Hamdane M; David-Cordonnier MH; D'Halluin JC
Oncogene; 1997 Nov; 15(19):2267-75. PubMed ID: 9393872
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.
Laneuville P; Sun G; Timm M; Vekemans M
Blood; 1992 Oct; 80(7):1788-97. PubMed ID: 1327283
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
[TBL] [Abstract][Full Text] [Related]
15. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
16. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H
Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266
[TBL] [Abstract][Full Text] [Related]
17. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
[TBL] [Abstract][Full Text] [Related]
18. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
19. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
20. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Hariharan IK; Adams JM; Cory S
Oncogene Res; 1988; 3(4):387-99. PubMed ID: 3147434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
